Technical Analysis for THRD - Third Harmonic Bio, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 12.92 | 0.08% | 0.01 |
THRD closed up 0.08 percent on Wednesday, May 15, 2024, on 59 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | 0.08% | |
New 52 Week High | Strength | 0.08% |
Alert | Time |
---|---|
Down 2 % | about 13 hours ago |
Down 1% | about 13 hours ago |
60 Minute Opening Range Breakdown | about 14 hours ago |
Reversed from Up | about 14 hours ago |
Up 1 ATR | about 14 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Allergy Type I Hypersensitivity Mast Cell Chronic Urticaria Immunoglobulin E
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Allergy Type I Hypersensitivity Mast Cell Chronic Urticaria Immunoglobulin E
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.68 |
52 Week Low | 4.36 |
Average Volume | 160,580 |
200-Day Moving Average | 8.69 |
50-Day Moving Average | 10.65 |
20-Day Moving Average | 11.65 |
10-Day Moving Average | 12.09 |
Average True Range | 0.70 |
RSI (14) | 68.15 |
ADX | 24.12 |
+DI | 33.27 |
-DI | 11.34 |
Chandelier Exit (Long, 3 ATRs) | 11.57 |
Chandelier Exit (Short, 3 ATRs) | 12.25 |
Upper Bollinger Bands | 12.84 |
Lower Bollinger Band | 10.45 |
Percent B (%b) | 1.03 |
BandWidth | 20.54 |
MACD Line | 0.51 |
MACD Signal Line | 0.42 |
MACD Histogram | 0.0916 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 14.63 | ||||
Resistance 3 (R3) | 14.69 | 14.19 | 14.35 | ||
Resistance 2 (R2) | 14.19 | 13.75 | 14.16 | 14.25 | |
Resistance 1 (R1) | 13.55 | 13.48 | 13.30 | 13.49 | 14.15 |
Pivot Point | 13.05 | 13.05 | 12.92 | 13.02 | 13.05 |
Support 1 (S1) | 12.41 | 12.61 | 12.16 | 12.35 | 11.69 |
Support 2 (S2) | 11.91 | 12.34 | 11.88 | 11.59 | |
Support 3 (S3) | 11.27 | 11.91 | 11.50 | ||
Support 4 (S4) | 11.21 |